PubRank

Deborah Young

Author PubWeight™ 41.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007 7.01
2 VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004 3.60
3 AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci 2005 1.92
4 Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 2009 1.66
5 Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003 1.32
6 AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 2008 1.31
7 Development and optimization of adeno-associated virus vector transfer into the central nervous system. Methods Mol Med 2003 1.23
8 Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012 1.22
9 IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 2008 1.17
10 AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004 1.16
11 In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010 1.09
12 Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther 2005 1.08
13 Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener 2007 1.06
14 IL-21 receptor is critical for the development of memory B cell responses. J Immunol 2010 1.05
15 Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging rats. Proc Natl Acad Sci U S A 2006 1.03
16 IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 2012 1.02
17 Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 2006 0.97
18 A novel role of circadian transcription factor DBP in hippocampal plasticity. Mol Cell Neurosci 2005 0.97
19 IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes 2011 0.92
20 Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 2003 0.92
21 Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med 2010 0.90
22 Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis. Arthritis Rheumatol 2014 0.87
23 Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size. Stroke 2013 0.86
24 Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia. J Neurochem 2007 0.85
25 Knockdown and overexpression of NR1 modulates NMDA receptor function. Mol Cell Neurosci 2009 0.84
26 Maximizing children's physical activity: an evaluability assessment to plan a community-based, multi-strategy approach in an ethno-racially and socio-economically diverse city. Health Promot Int 2003 0.84
27 Gene regulation systems for gene therapy applications in the central nervous system. Neurol Res Int 2012 0.83
28 Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood. J Transl Med 2010 0.80
29 Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody. J Transl Med 2010 0.80
30 Nucleic Acid-Based Therapy Approaches for Huntington's Disease. Neurol Res Int 2012 0.80
31 HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity. Mol Ther 2008 0.79
32 Phosphorylation-dependent degradation of transgenic CREB protein initiated by heterodimerization. Brain Res 2006 0.76
33 TERN Residency Program: transitioning the experienced registered nurse. J Nurses Prof Dev 2014 0.75